Fig. 3

(a-b) Metabolic activity inhibition of E. coli and S. aureus at 0 and 24 h by compound 2 and 3 compared with ciprofloxacin and gentamicin. 2A: compound 2 at 1 mg/mL; 2B: compound 2 at 0.063 mg/mL MIC against E. coli and S. aureus; 3A: compound 3 at 1 mg/mL; 3B: compound 3 at 0.125 mg/mL against E. coli and 0.032 mg/mL against S. aureus